Lipid Nanoparticle CDMO Services Market
完整報告名稱與涵蓋範圍
Lipid Nanoparticle CDMO Services Market Size, Share & Trends Analysis Report, By Service Type (Formulation Development and Optimization, GMP LNP Manufacturing, Analytical Characterization and Release Testing, Fill-Finish and Cold Chain Supply), By Payload Type (mRNA and Self-Amplifying RNA, siRNA and Oligonucleotides, Gene Editing Payloads, Small Molecules and Other Payloads), By Scale (Preclinical and Clinical, Commercial), By End User, By Region, and Segment Forecasts, 2026-2035
報告摘要
The lipid nanoparticle CDMO services market covers outsourced formulation development, GMP manufacturing, analytical characterisation and fill-finish of lipid nanoparticle drug products encapsulating mRNA, self-amplifying RNA, siRNA, gene-editing components and other payloads, at clinical and commercial scale. Lipid raw material supply, mRNA drug substance manufacturing and captive nanoparticle production by originators are excluded.
Demand has broadened from pandemic vaccine supply to a diverse pipeline of RNA vaccines, therapeutic proteins, in vivo gene editing and in vivo cell therapy programs, most of which lack in-house nanoparticle expertise and microfluidic or impingement-jet mixing capacity. Providers are investing in scalable mixing platforms, closed aseptic formulation suites, particle characterisation laboratories and integrated offers that combine lipid supply, drug substance and drug product, while sponsors seek flexibility for small clinical batches and reliable commercial capacity. Lipid intellectual property licensing, the need for robust critical quality attribute control and cold-chain logistics for finished product influence provider selection.
Europe and North America host the leading providers, with China, South Korea and Singapore adding capacity alongside domestic RNA pipelines. Competition involves lipid and excipient companies integrating downstream, biologics CDMOs adding nanoparticle suites and specialised nanomedicine manufacturers.
The InsightAce study delivers revenue forecasts in US$ across all service type, payload type, scale and end user and regional segments for 2026-2035, alongside segment-level trend analysis, competitive landscape assessment and detailed company profiling.
授權報價
| Single User | $4,500 USD |
| Enterprise / Global Site Licence | $9,500 USD |
目錄 Table of Contents
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Lipid Nanoparticle CDMO Services Market Snapshot
Chapter 4. Global Lipid Nanoparticle CDMO Services Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Market Drivers
4.3. Market Challenges
4.4. Emerging Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis - Porter's Five Forces Analysis
4.7. Competitive Landscape and Market Positioning
4.8. Market Opportunity Analysis
Chapter 5. Market Segmentation 1: By Service Type Estimates & Trend Analysis
5.1. Service Type & Market Share, 2026 & 2035
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by Service Type:
5.2.1. Formulation Development and Optimization
5.2.2. GMP LNP Manufacturing
5.2.3. Analytical Characterization and Release Testing
5.2.4. Fill-Finish and Cold Chain Supply
Chapter 6. Market Segmentation 2: By Payload Type Estimates & Trend Analysis
6.1. Payload Type & Market Share, 2026 & 2035
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by Payload Type:
6.2.1. mRNA and Self-Amplifying RNA
6.2.2. siRNA and Oligonucleotides
6.2.3. Gene Editing Payloads
6.2.4. Small Molecules and Other Payloads
Chapter 7. Market Segmentation 3: By Scale Estimates & Trend Analysis
7.1. Scale & Market Share, 2026 & 2035
7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by Scale:
7.2.1. Preclinical and Clinical
7.2.2. Commercial
Chapter 8. Market Segmentation 4: By End User Estimates & Trend Analysis
8.1. End User & Market Share, 2026 & 2035
8.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by End User:
8.2.1. Pharmaceutical Companies
8.2.2. Biotechnology Companies
8.2.3. Academic and Government Sponsors
Chapter 9. Lipid Nanoparticle CDMO Services Market: Regional Estimates & Trend Analysis
9.1. North America
9.1.1. United States
9.1.2. Canada
9.2. Europe
9.2.1. Germany
9.2.2. United Kingdom
9.2.3. France
9.2.4. Italy
9.2.5. Spain
9.2.6. Rest of Europe
9.3. Asia Pacific
9.3.1. China
9.3.2. Japan
9.3.3. India
9.3.4. South Korea
9.3.5. Australia
9.3.6. Southeast Asia
9.3.7. Rest of Asia Pacific
9.4. Latin America
9.4.1. Brazil
9.4.2. Mexico
9.4.3. Rest of Latin America
9.5. Middle East & Africa
9.5.1. GCC Countries
9.5.2. South Africa
9.5.3. Rest of Middle East & Africa
Chapter 10. Competitive Landscape
10.1. Company Market Positioning Analysis
10.2. Strategic Developments (Partnerships, Expansions, Product Launches, M&A)
Chapter 11. Company Profiles
11.1. CordenPharma International
11.2. Evonik Industries AG
11.3. Lonza Group AG
11.4. Novo Nordisk A/S (Catalent)
11.5. Curapath
11.6. Polymun Scientific Immunbiologische Forschung GmbH
11.7. Aldevron (Danaher)
11.8. Thermo Fisher Scientific Inc.
11.9. Samsung Biologics Co., Ltd.
11.10. Acuitas Therapeutics Inc.
11.11. Genevant Sciences
11.12. Ardena
11.13. Recipharm AB
11.14. Exelead (Merck KGaA)
11.15. Vernal Biosciences
圖表清單 List of Tables & Figures
Table 1. Global Lipid Nanoparticle CDMO Services Market Revenue Forecast by Service Type, 2026-2035 (US$ Mn)
Figure 1. Global Lipid Nanoparticle CDMO Services Market Segmentation and Scope Overview
Table 2. Global Lipid Nanoparticle CDMO Services Market Revenue Forecast by Payload Type, 2026-2035 (US$ Mn)
Figure 2. Global Lipid Nanoparticle CDMO Services Market Share by Service Type, 2026 & 2035
Table 3. Global Lipid Nanoparticle CDMO Services Market Revenue Forecast by Scale, 2026-2035 (US$ Mn)
Figure 3. LNP Drug Product Manufacturing Workflow and Outsourcing Points
Table 4. Global Lipid Nanoparticle CDMO Services Market Revenue Forecast by End User, 2026-2035 (US$ Mn)
Figure 4. Clinical and Commercial LNP Formulation Capacity by Provider and Region
Table 5. Global Lipid Nanoparticle CDMO Services Market Revenue Forecast by Region, 2026-2035 (US$ Mn)
Figure 5. Asia Pacific Lipid Nanoparticle CDMO Services Growth Opportunity Analysis
Table 6. North America Lipid Nanoparticle CDMO Services Market Revenue by Country, 2026-2035 (US$ Mn)
Figure 6. Competitive Positioning of Key Lipid Nanoparticle CDMO Services Market Participants
Table 7. Europe Lipid Nanoparticle CDMO Services Market Revenue by Country, 2026-2035 (US$ Mn)
Figure 7. Porter's Five Forces Analysis of the Global Lipid Nanoparticle CDMO Services Market
Table 8. Asia Pacific Lipid Nanoparticle CDMO Services Market Revenue by Country, 2026-2035 (US$ Mn)
Figure 8. Payload Diversification of the LNP Pipeline Beyond Vaccines, 2026-2035
Table 9. Strategic Developments of Leading Lipid Nanoparticle CDMO Services Market Participants, 2023-2026
提及公司
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 InsightAce Analytic 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們